Glepaglutide
Also called ZP1848
Subcutaneous (under the skin)Human study reference
Research reference
Human study
EASE SBS-1 phase 3 trial
Separate 10 mg once-weekly and twice-weekly groups
24 weeks
EASE SBS-1, Gastroenterology (2025) ↗When results may show
- When change was measured
- The twice-weekly group reduced parenteral support versus placebo at week 24; the once-weekly group did not show a significant primary-endpoint difference.
- When to assess
- 24 weeks
- Conditions and limitations
- 106 adults with short-bowel intestinal failure needing parenteral support at least 3 days/week. Specialist fluid-balance-guided support changes were part of the study. Do not present the two groups as interchangeable personal options.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: EASE SBS-1, Gastroenterology (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Glepaglutide describe 10–10 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.08× single dose
- Time to steady state
- 10.4days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- EASE SBS-1, Gastroenterology (2025)Specialist fluid-balance-guided support changes were part of the study. Do not present the two groups as interchangeable personal options.